SS-31

• An Intermediate Size Expanded Access Protocol of Elamipretide
  Unknown Phase AVAILABLE Stealth BioTherapeutics Inc.
• ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
  PHASE3 ACTIVE_NOT_RECRUITING Stealth BioTherapeutics Inc.
• Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)
  PHASE3 COMPLETED Stealth BioTherapeutics Inc.
• A Trial to Evaluate Safety and Efficacy of Elamipretide Primary Mitochondrial Myopathy Followed by Open-Label Extension
  PHASE3 TERMINATED Stealth BioTherapeutics Inc.
• A Trial to Evaluate Safety, Tolerability and Efficacy of Elamipretide in Subjects With Barth Syndrome
  PHASE2, PHASE3 COMPLETED Stealth BioTherapeutics Inc.

Showing 5 of 31 trials.

• Mechanisms of Anti-Oxidants, N-Acetylcysteine and Elamipretide (SS-31), on Ozone-Induced Airway Hyperresponsiveness and Mucus Hypersecretion.
  Lung unknown
• Disruption of hippocampal mitochondrial function underlies opioid-induced postoperative cognitive dysfunction in aged rats.
  bioRxiv unknown
• Restoring cardiolipin homeostasis mitigates cerebral ischemia-reperfusion injury by suppressing ATG5-mediated neuronal autophagy-dependent ferroptosis.
  J Adv Res unknown
• Early targets and progressive deterioration in cardiac performance in response to chronically modified cardiac troponin I.
  Am J Physiol Heart Circ Physiol unknown
• Breaking a mitochondrial danger-STING feed-forward amplifier preserves alveolar-capillary architecture and dampens interferon-chemokine signaling in acute lung injury.
  Tissue Cell unknown

Showing 5 of 20 papers by citation count.

FDA Data

Frequently Asked Questions